Compare JD.Com Inc (JD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Neurocrine Biosciences Inc — how do they compare? JD.Com Inc trades at $30.45 (market cap $41.80B), while Neurocrine Biosciences Inc trades at $178.49 (market cap $17.40B). The key difference: JD.Com Inc is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and JD.Com Inc pays a 3.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| JD | NBIX | |
|---|---|---|
Market Cap | $41.80B | $17.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $180.55 |
52-Week Low | $25.19 | $123.10 |
Enterprise Value | $27.96B | $16.49B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
